# GLP1 Periconception Exposure and OB Outcomes

Page: https://stenobird.com/podcast/dr-chapa-s-obgyn-no-spin-podcast-7407953/glp1-periconception-exposure-and-ob-outcomes
Text version: https://stenobird.com/podcast/dr-chapa-s-obgyn-no-spin-podcast-7407953/glp1-periconception-exposure-and-ob-outcomes.md
Podcast: [Dr. Chapa's OBGYN No Spin Podcast](https://stenobird.com/podcast/dr-chapa-s-obgyn-no-spin-podcast-7407953)
Published: 2026-05-04T11:00:00+00:00
Episode link: https://rss.com/podcasts/dr-chapa-s-obgyn-no-spin-podcast/2786178
Audio file: https://content.rss.com/episodes/337911/2786178/dr-chapa-s-obgyn-no-spin-podcast/2026_05_01_18_07_46_b22cdd98-9808-420c-adf5-260884c0d44d.mp3
Processing state: processed
JSON: https://stenobird.com/v1/public/podcasts/dr-chapa-s-obgyn-no-spin-podcast-7407953/episodes/glp1-periconception-exposure-and-ob-outcomes
Duration seconds: 1293

## Resource

There is no denying it, you know of one or MORE individuals or patients currently on a GLP1 agent. Although not FDA approved for PCOS as a stand-alone diagnosis, there is growing evidence supporting their offlabel use in PCOS, and international guidelines now include them as a conditional recommendation. In women, the weight loss associated with these medications may trigger the return of spontaneous ovulation, making mistimed pregnancy a possibility. A key study by Sanz and Blázquez (back in 2011) demonstrated that both GLP-1 and the GLP-1 receptor are present in mouse embryos as early as embryonic day 6 (E6) and continue through the first trimester, as well as in pluripotent mouse embryonic stem cells. In these undifferentiated cells, GLP-1 modified the expression of endodermal, ectodermal, and mesodermal gene markers, as well as critical developmental signaling molecules. So, there is a concern about embryogenesis if inadvertent exposure to these meds occurs in early pregnancy. In this episode, we will summarize 2 recent and separate systematic reviews (March 2026; April 2026) on fetal/OB outcomes after periconceptional exposure. This builds on the Parker data set from 2025. One of these reviews, from April 2026, is also a meta-analysis. Listen in for details. 1. Ozbek L, Shah E, Al-Shiab R, Inal A, Guldan M, Afsar B, Covic A, Kanbay M. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab. 2026 Mar 26. https://pubmed.ncbi.nlm.nih.gov/41885132/ 2. Hakim J, Rajesh D, Tello J. Neonatal and Obstetric Outcomes Following Periconceptional Exposure to Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-analysis. AJOG; April 28, 2…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/dr-chapa-s-obgyn-no-spin-podcast-7407953/episodes/glp1-periconception-exposure-and-ob-outcomes/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/dr-chapa-s-obgyn-no-spin-podcast-7407953/glp1-periconception-exposure-and-ob-outcomes.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.